ICU Medical (NASDAQ:ICUI) Stock Gets Price Target Increase from KeyCorp

ICU Medical (NASDAQ:ICUI) had its price objective boosted by equities researchers at KeyCorp from $187.00 to $189.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp‘s price target would suggest a potential upside of 9.81% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Piper Sandler raised their target price on shares of ICU Medical from $195.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday. Raymond James Financial restated a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Needham & Company LLC upped their price target on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $195.20.

ICU Medical Trading Up 2.7%

NASDAQ:ICUI opened at $172.11 on Friday. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of 72.01, a PEG ratio of 2.17 and a beta of 0.88. ICU Medical has a 52 week low of $113.37 and a 52 week high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The firm has a 50 day moving average of $162.91 and a 200 day moving average of $149.27.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.30. The business had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a return on equity of 8.46% and a net margin of 2.76%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.03 earnings per share. As a group, sell-side analysts anticipate that ICU Medical will post 7.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, Director Elisha W. Finney sold 378 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the transaction, the director directly owned 4,871 shares in the company, valued at $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel Woolson sold 5,417 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the transaction, the vice president owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. This represents a 24.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,830 shares of company stock worth $3,905,003 over the last ninety days. 2.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Gagnon Securities LLC raised its position in ICU Medical by 0.8% during the 3rd quarter. Gagnon Securities LLC now owns 29,630 shares of the medical instruments supplier’s stock worth $4,756,000 after buying an additional 230 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of ICU Medical by 52.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 5,549 shares of the medical instruments supplier’s stock worth $891,000 after acquiring an additional 1,914 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of ICU Medical in the third quarter valued at about $987,000. Illinois Municipal Retirement Fund boosted its holdings in shares of ICU Medical by 9.2% in the third quarter. Illinois Municipal Retirement Fund now owns 13,788 shares of the medical instruments supplier’s stock valued at $2,213,000 after acquiring an additional 1,162 shares in the last quarter. Finally, Lido Advisors LLC boosted its holdings in shares of ICU Medical by 15.4% in the third quarter. Lido Advisors LLC now owns 3,707 shares of the medical instruments supplier’s stock valued at $595,000 after acquiring an additional 494 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.